Shots:

• The P-III (explorer7) study evaluates concizumab in a ratio (1:2) in 7133 males aged ≥12yrs. patients with haemophilia A or B with/out inhibitors
• The results showed an 86% reduction in treated spontaneous & traumatic bleeds, mean ABR of 1.7 vs 11.8 with no prophylaxis & overall median ABR was 0 vs 9.8, 63.6% vs 10.5% experienced no treated bleeds. The safety & tolerability profile was within the expected range with no thromboembolic events reported after treatment restart
• The company is expected to submit for regulatory approval of concizumab for prophylactic treatment of haemophilia A or B with inhibitors in H2’22 in the US & Japan and 2023 in the EU & the UK. The therapy is also being studied in (explorer10) paediatric study & is expected to be complete in 2026

Ref: GlobeNewswire | Image: Novo Nordisk